Form 4: Sera Prognostics Director Ryan Trimble Receives Significant Equity Awards

Sera Prognostics, Inc. Director Ryan Trimble was granted 15,596 restricted stock units and 25,000 stock options as part of his compensation, vesting over one year.

Summary

• Ryan Trimble, a Director of Sera Prognostics, Inc. (SERA), reported the acquisition of equity awards on June 5, 2025.
• Mr. Trimble acquired 15,596 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs), granted at a price of $0.
• These RSUs are scheduled to vest in monthly installments over one year, commencing June 5, 2025, contingent on his continued service to the issuer.
• Following this transaction, Mr. Trimble directly beneficially owns 22,713 shares of Class A Common Stock.
• Additionally, Mr. Trimble was granted 25,000 stock options with an exercise price of $1.6 per share on June 5, 2025.
• These stock options also vest in monthly installments over one year, starting June 5, 2025, and have an expiration date of June 5, 2035.
• The stock options were granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The filing indicates a routine grant of equity compensation to a director, which is a positive for aligning management incentives with shareholder interests and retaining key personnel. There are no negative implications or red flags within this specific filing.

Positives

• The grant of restricted stock units (RSUs) and stock options to Director Ryan Trimble aligns his interests with those of shareholders, incentivizing long-term performance.
• The one-year vesting schedule for both RSUs and stock options encourages continued service and commitment from the director.

Future Outlook

The vesting schedule for both RSUs and stock options, extending over one year from June 5, 2025, indicates an expectation of continued service from Director Ryan Trimble, aligning his future incentives with the company's performance.

Industry Context

The grant of equity awards to a non-employee director is a common practice across industries, particularly in growth-oriented companies like those in the biotechnology or diagnostics sector, to attract and retain talent and align director incentives with long-term shareholder value.

Comparison to Industry Standards

• The compensation structure, involving restricted stock units and stock options with a one-year vesting period, is consistent with typical non-employee director compensation policies observed in publicly traded companies, especially within the biotech and healthcare diagnostics sectors.
• Companies such as Exact Sciences Corp. (EXAS) or Natera, Inc. (NTRA) often utilize similar equity-based incentives for their board members to foster long-term commitment and align interests with company performance.

Corporate Governance

Related Party Transactions

• Grant of restricted stock units and stock options to Ryan Trimble, a Director of Sera Prognostics, Inc., as part of his compensation package.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the long-term performance of the company, potentially leading to better governance and strategic decisions.
• Employees: While not directly impacted, a stable and incentivized board can contribute to overall company stability and growth.

Next Steps

• The restricted stock units and stock options granted to Director Ryan Trimble will vest in monthly installments over one year, commencing June 5, 2025, subject to his continued service.

Key Dates

Recommendation

Keywords

Sera Prognostics, SERA, Form 4, Ryan Trimble, Director, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Insider Transaction